When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research
Neuroethics November 6, 2023 Edward Jacobs, Ashleigh Murphy-Beiner, Ian Rouiller et al. 23 citations
In psychedelic clinical trials, the case for providing patients with continued access to the investigational drug after the trial ends is especially strong due to the drugs' broader legal status, the unique therapist-participant relationship, and the extended therapeutic process. Because the therapy's effectiveness relies heavily on non-drug factors and the cultural setting, the authors argue for expanding post-trial care beyond just drug access. They outline potential provisions and contend that viewing post-trial care as an integral part of research—and a proper use of funding—will help build the infrastructure needed for a future psychedelic medicine system after legalization.